Tony Holler thinks there’s still an even chance U.S. regulatory authorities will find a way to import his company’s surplus influenza vaccine to help fill a gaping void created by the unexpected loss of half the U.S. annual supply of flu shots.The president of ID Biomedical, Holler says there is serious interest among U.S. regulators in figuring out how to legally purchase flu vaccine from companies not currently licensed to sell in that country.
